Drug intelligence / Profile preview

BJ008

Development stage: Preclinical
Lead developer: Shanghai Bao Pharmaceuticals
Administration: Subcutaneous

Overview

BJ008 is a subcutaneous formulation currently in preclinical development by Shanghai Bao Pharmaceuticals. It is part of the company's specialized pipeline focused on subcutaneous drug delivery systems, which typically aim to convert intravenous therapies into subcutaneous injections to improve patient convenience and optimize pharmacokinetic profiles. As of early 2024, the specific active pharmaceutical ingredient and the therapeutic target for BJ008 have not been publicly disclosed by the developer.

Beyond the preview

Go deeper on BJ008.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BJ008.

Explore the full profile